Veracyte Announces Medicare Coverage

Posted by
|

“Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the company’s Afirma Gene Expression Classifier for use in thyroid nodule diagnosis. This means that Veracyte’s genomic test is now accessible to 40 million Medicare patients nationwide.

Clinical data has shown that Veracyte’s test helps resolve inconclusive results on thyroid nodule fine needle aspiration (FNA) samples being tested for cancer with a high degree of accuracy, demonstrating potential to help tens of thousands of patients each year avoid surgery.

Thyroid cancer is the fastest-growing cancer in the United States, with an estimated 48,020 new cases expected in 2011, according to the American Cancer Society. Approximately 450,000 thyroid nodule FNAs – a minimally…”

To continue reading the full press release from Veracyte, please click here.

 

Add a comment

You must be logged in to comment.

Subscribe